Not content with taking on the respiratory syncytial virus (RSV) prevention market with its antibody-based therapy Beyfortus, AstraZeneca has agreed to buy US biotech Icosavax and its phase 3 ...
IVXA-12 is under clinical development by Icosavax and currently in Phase II for Respiratory Syncytial Virus (RSV) Infections. According to... Likelihood of Approval and Phase Transition Success Rate ...
DiveWire guarantees visibility for your news announcements through instant distribution to BioPharma Dive’s audience and its 153,500 newsletter subscribers for 21 days.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback